NCT04600115RecruitingEarly phase 1
New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
This study's main specific aims are; 1. To develop robust acquisition and reconstruction methods specifically for the study of microvascular cardiac remodeling with MRI which will include very innovative quantitative perfusion methods, as well as fibrosis quantification, longitudinal strain, and phase contrast imaging for flow. 2. Test the new methods for identifying the clinical task of characterizing HFpEF.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 21 Oct 2020
- Start date
- 3 Mar 2017
- Primary completion date
- 3 Mar 2027
- Lead sponsor
- University of Utah
- Diseases
- Heart failure
- NCT number
- NCT04600115
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 100
- From 3 Mar 2017 to the primary completion date, 3 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All participants that will receive a stress agent will refrain from consuming caffeine for at least 12 hours prior to each MRI
Other illness
- Critically ill patients, patients on ventilators, patients with unstable angina or with hypotension, asthmatics, and other patients whose medical care or safety may be at risk from undergoing an MRI examination will be excluded.
- Patients with contraindication to MRI (metal implants, or certain types of heart valves),
- Patients with a known allergy or contraindication to Adenosine and/or Regadenoson will be excluded from stress MRI cohorts.
Lab values
- Gadolinium nephrotoxicity will be addressed by having patients with abnormal kidney function (GFR\<30) excluded from the study due to the (very small) risk associated with gadolinium contrast agents.
Other
- minors
- Patients with claustrophobia will also be excluded from the study if this cannot be controlled with standard methods (valium or benadryl).
- pregnant patients, , mentally disabled patients and prisoners will be excluded from this study. (All criteria apply to patients and normal volunteers).
- This threshold may be modified, depending on practices determined by the Radiology Department and the IRB.
- Subjects with a known contraindication to Adenosine and/or Regadenoson will only be enrolled in scans where no stress agent will be administered
Who the study is looking for
- All participants will be over the age of 18 and able to provide consent
- Group A (volunteers, with or without cardiac disease): Volunteers will be available for at least one study visit
- Group B (HFpEF patient volunteers): Volunteers will have a diagnosis of HFpEF and be safe to be imaged with MRI
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| university of Utah, Radiology Research Coordinator of this site? Confirm its status | Salt Lake City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.